Document:

Exhibit 4.19

 

REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION
RIGHTS AGREEMENT (the “Agreement”) is dated as of May 21, 2019, by and between JMU Limited, an exempted company
duly incorporated and validly existing under the laws of Cayman Islands (the “Company”) and Mr. Haohan Xu,
an U.S. citizen with the passport No. ********** (“Right Holder”).
The Company and the Rights Holders are each referred to herein as a “Party,” and collectively as the “Parties.”

 

WHEREAS, the Company,
the Rights Holder and Unicorn Investment Limited, a company duly incorporated and validly existing under the laws of the British
Virgin entered into a Share Purchase Agreement dated May 21, 2019 (the “Share Purchase Agreement”), pursuant
to which the Company agreed to enter into a registration rights agreement with the Rights Holder at or prior to the occurrence
of the closing contemplated under the Share Purchase Agreement.

 

NOW, THEREFORE, in
consideration of the mutual promises made in this Agreement, and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Parties hereby agree as follows:

 

		1.	DEFINITIONS

 

		1.1	Definitions.

 

As used in this Agreement,
the following terms have the respective meaning set forth below:

 

	“ADSs”	means the American depositary shares of the Company; 
	 	 
	“Affiliate”	means, with respect to any specified Person, any other Person who or which, directly or indirectly, controls, is controlled by, or is under common control with such specified Person, including, without limitation, any officer, director, employee, member, partner or shareholder of such Person and any venture capital fund now or hereafter existing that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company with, such Person;
	 	 
	“Agreement”	has the meaning set forth in the preamble;
	 	 
	“automatic shelf registration statement”	has the meaning set forth in Section 2.4(j);
	 	 
	“Company”	has the meaning set forth in the preamble;
	 	 
	“Company Securities”	means (i) Ordinary Shares, (ii) securities convertible into or exchangeable for Ordinary Shares, (iii) any options, warrants or other rights to acquire Ordinary Shares and (iv) any depositary receipts or similar instruments issued in respect of Ordinary Shares;

 

    1

     

    

 

	“Exchange Act”	means the Securities Exchange Act of 1934 of the United States, as amended (and any successor thereto), and the rules and regulations promulgated thereunder;
	 	 
	“Form F-3”	means such respective forms under the Securities Act as in effect on the date hereof or any successor form under the Securities Act that permits significant incorporation by reference of the Company’s subsequent public filings under the Exchange Act;
	 	 
	“HKIAC”	has the meaning set forth in Section 3.11;
	 	 
	“Immediate Family Member”	has the meaning set forth in Section 2.11;
	 	 
	“Initiating Holders”	has the meaning set forth in Section 2.1(b);
	 	 
	“Ordinary Shares”	means the ordinary shares in the capital of the Company, par value of US$0.00001 per share;
	 	 
	“Person”	means any individual, corporation, partnership, trust, limited liability company, association or other entity;
	 	 
	“register,” “registered,” or “registration”	Refers to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or documents;
	 	 
	“Registrable Securities”	means (i) any Ordinary Shares acquired by the Rights Holder pursuant to the Share Transfer Agreements, and (ii) any other Ordinary Shares of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares listed in clauses (i); provided, however, that the foregoing definition shall exclude in all cases any Registrable Securities sold by a person in a transaction in which his or her rights under this Agreement are not assigned. Notwithstanding the foregoing, Ordinary Shares or other securities shall only be treated as Registrable Securities if and so long as (A) they have not been sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, (B) they have not been sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale, or (C) the Rights Holder thereof is entitled to exercise any right provided in Article 2 in accordance with Section 2.13 below;

 

    2

     

    

 

	“Registrable Securities then outstanding”	means the number of Ordinary Shares of the Company that are Registrable Securities and are then issued and outstanding or would be outstanding assuming full conversion of all securities, warrants or other rights which are, directly or indirectly, convertible, exercisable or exchangeable into or for Registrable Securities;
	 	 
	“Rights Holder”	has the meaning set forth in the preamble;
	 	 
	“SEC”	means the United States Securities and Exchange Commission;
	 	 
	“Securities Act”	means the United States Securities Act of 1933, as amended (and any successor thereto) and the rules and regulations promulgated thereunder;
	 	 
	“Share Purchase Agreement”	has the meaning set forth in the recitals;
	 	 
	“Share Transfer Agreements”	means the share transfer agreements entered into by and between the Rights Holder and certain other parties, respectively; 
	 	 
	“Violation”	has the meaning set forth in Section 2.9(a);
	 	 
	“WKSI”	has the meaning set forth in Section 2.4(j);

 

		2.	REGISTRATION RIGHTS

 

		2.1	Request for Registration.

 

		(a)	If the Company shall receive at any time a written request from the Rights Holder of at least ten
percent (10%) of the Registrable Securities then outstanding that the Company file a registration statement under the Securities
Act with an anticipated aggregate offering price (before deduction of underwriting discounts, commissions and expenses) of at least
US$5,000,000 then the Company shall, within ten (10) days of the receipt thereof, give written notice of such requests to the Rights
Holder and shall, subject to the limitations of Section 2.1(b), use its best efforts to file as soon as practicable, and
in any event within ninety (90) days of the receipt of such requests, a registration statement under the Securities Act covering
all Registrable Securities which the Rights Holder requests to be registered within twenty (20) days of the mailing of such notice
by the Company;

 

    3

     

    

 

		(b)	If the Rights Holder initiating the registration request hereunder (“Initiating Holders”)
intend to distribute the Registrable Securities covered by his request by means of an underwriting, he shall so advise the Company
as a part of his request made pursuant to this Section 2.1 and the Company shall include such information in the written
notice referred to in Section 2.1(a). The underwriter will be selected by a majority in interest of the Initiating Holders
and shall be reasonably acceptable to the Company. In such event, the right of the Rights Holder to include his Registrable Securities
in such registration shall be conditioned upon such holder’s participation in such underwriting and the inclusion of such
Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders
and such holder) to the extent provided herein. The Rights Holder proposing to distribute his securities through such underwriting
shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with
the underwriter or underwriters of internationally recognized standing selected for such underwriting reasonably acceptable to
the holders of at least a majority of the voting power of all Registrable Securities proposed to be included in such registration.
Notwithstanding any other provision of this Section 2.1, if the underwriter advises the Initiating Holders in writing that
marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise
all holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of such Registrable
Securities that may be included in the underwriting shall be allocated among the participating Rights Holder thereof, including
the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities owned by the participating
Rights Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall
not be reduced unless all other Company Securities are first entirely excluded from the underwriting; provided further that any
Initiating Holder shall have the right to withdraw its request for registration from the underwriting by written notice to the
Company and the underwriters delivered at least ten (10) days prior to the effective date of the registration statement, and such
withdrawal request for registration shall not be deemed to constitute one of the registration rights granted pursuant to this Section
2.1. If the Rights Holder disapproves the terms of any underwriting, such holder may elect to withdraw therefrom by written
notice to the Company and the underwriters delivered at least ten (10) days prior to the effective date of the registration statement.
Any Registrable Securities excluded or withdrawn from such underwritten offering shall be withdrawn from the registration. To facilitate
the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares
allocated to the Rights Holder to the nearest one hundred (100) shares.

 

		(c)	Notwithstanding the foregoing, if the Company shall furnish to Rights Holder requesting a registration
statement pursuant to this Section 2.1, a certificate signed by the Chief Executive Officer of the Company stating that
in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its shareholders
for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the
Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after receipt of
the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than once in any 12-month
period; provided further that during such one hundred twenty (120)-day period, the Company shall not file any registration statement
pertaining to the public offering of any Company Securities.

 

    4

     

    

 

		(d)	In addition, the Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to this Section 2.1:

 

		(i)	after the Company has effected six (6) registrations pursuant to this Section 2.1 and such
registrations have been declared or ordered effective;

 

		(ii)	in response to the demand for registration by any Initiating Holder or any of its Affiliates pursuant
to this Section 2.1, after the Company has effected two (2) registrations pursuant to such Initiating Holder’s or
its Affiliate’s demand for registration pursuant to this Section 2.1 and such registrations have been declared or
ordered effective;

 

		(iii)	during the period starting with the date ninety (90) days prior to the Company’s good faith
estimate of the date of filing of, and ending on a date ninety (90) days after the effective date of, a registration subject to
Section 2.2 hereof; provided that the Company is actively employing in good faith its best efforts to cause such registration
statement to become effective and that the Holders are entitled to join such registration in accordance with Section 2.2
hereof; or

 

		(iv)	if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form F-3 pursuant to a request made pursuant to Section 2.3 below.

 

		2.2	Piggyback Registration.

 

If (but without any obligation
to do so) the Company proposes to register (including for this purpose a registration effected by the Company for shareholders
other than the Rights Holder) any of Company Securities under the Securities Act in connection with the public offering of such
securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company share
option, share purchase or similar plan or a transaction covered by Rule 145 under the Securities Act, a registration in which the
only shares being registered are Ordinary Shares issuable upon conversion of debt securities which are also being registered, or
any registration on any form which does not include substantially the same information as would be required to be included in a
registration statement covering the sale of the Registrable Securities), the Company shall, at such time, promptly give the Rights
Holder written notice of such registration. Upon the written request of the Rights Holder given within twenty (20) days after mailing
of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the provisions of Section
2.7, use its best efforts to cause to be registered under the Securities Act all of the Registrable Securities that such Rights
Holder has requested to be registered. Registration pursuant to this Section 2.2 shall not be deemed to be a demand registration
as described in Section 2.1 above. If the Rights Holder decides not to include all or any of its Registrable Securities
in such registration by the Company, such Rights Holder shall nevertheless continue to have the right to include any Registrable
Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings
of Company Securities, all upon the terms and conditions set forth herein. There shall be no limit on the number of times the Rights
Holder may request registration of Registrable Securities under this Section 2.2.

 

    5

     

    

 

		2.3	Form F-3 Registration.

 

The Company shall use its best
efforts to qualify for registration on Form F-3. In case the Company shall receive from the Rights Holder a written request that
the Company effect a registration on Form F-3 or any comparable or successor form and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Rights Holder, the Company shall:

 

		(a)	promptly give written notice of the proposed registration, and any related qualification or compliance,
to all other rights holders;

 

		(b)	use its best efforts to effect, as soon as practicable, such registration and all such qualifications
and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such
Rights Holder’s Registrable Securities as are specified in such request, in a written request given within 15 days after
receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any
such registration, qualification or compliance, pursuant to this Section 2.3:

 

		(i)	if Form F-3 is not available for such offering by the Rights Holder;

 

		(ii)	if the Rights Holder intends to sell Registrable Securities at an aggregate price to the public
(after the deduction of any underwriters’ discounts or commissions) of less than US$500,000;

 

		(iii)	if the Company shall furnish to the Rights Holder a certificate signed by the Chief Executive Officer
of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental
to the Company and its shareholders for such Form F-3 Registration to be effected at such time, in which event the Company shall
have the right to defer the filing of the Form F-3 registration statement for a period of not more than one hundred twenty (120)
days after receipt of the request of the rights Holder(s) under this Section 2.3; provided, however, that the Company shall
not utilize this right more than once in any 12-month period; provided further that during such one hundred twenty (120)-day period,
the Company shall not file any registration statement pertaining to the public offering of any Company Securities ; or

 

		(iv)	if, within the 12-month period preceding the date of such request, the Company has already effected
two (2) registrations on Form F-3 for the Rights Holder pursuant to this Section 2.3; or (v) during the period ending one
hundred eighty (180) days after the effective date of a registration statement subject to Section 2.2; provided that the
Rights Holder is entitled to join such registration in accordance with Section 2.2 hereof; and

 

    6

     

    

 

		(c)	Subject to the foregoing, the Company shall file a registration statement covering the Registrable
Securities as soon as practicable after receipt of the request or requests of the Rights Holder. Registrations effected pursuant
to this Section 2.3 shall not be counted as demands for registration or registrations effected pursuant to Sections 2.1
or 2.2, respectively. Subject to the Section 2.3(b), there shall be no limit on the number of times the Rights Holder
may request registration of Registrable Securities under this Section 2.3.

 

		2.4	Obligations of the Company.

 

Whenever required under this
Article 2 Whenever required under this Article 2 to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible:

 

		(a)	Prepare and file with the SEC a registration statement with respect to such Registrable Securities,
and use its best efforts to cause such registration statement to become effective, and, upon the request of the Rights Holder of
a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to ninety (90)
days or until the distribution described in such registration statement is completed, if earlier. In the case of any registration
of Registrable Securities on Form F-3 which are intended to be offered on a continuous or delayed basis, such ninety (90)-day period
shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided
that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided
further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment permit, in lieu
of filing a post-effective amendment that (i) includes any prospectus required by Section 10(a)(3) of the Securities Act
or (ii) reflects facts or events representing a material or fundamental change in the information set forth in the registration
statement, the incorporation by reference of information required to be included in (i) and (ii) above to be contained in periodic
reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement;

 

		(b)	Prepare and file with the SEC such amendments and supplements to such registration statement and
the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities
Act with respect to the disposition of all securities covered by such registration statement for up to ninety (90) days or until
the distribution described in such registration statement is completed, if earlier;

 

		(c)	Furnish to the Rights Holder such numbers of copies of a prospectus, including a preliminary prospectus,
in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to
facilitate the disposition of Registrable Securities owned by them;

 

    7

     

    

 

		(d)	Use its best efforts to register and qualify the securities covered by such registration statement
under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Rights Holder, provided
that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions;

 

		(e)	In the event of any underwritten public offering, enter into and perform its obligations under
an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. The Rights Holder participating
in such underwriting shall also enter into and perform its obligations under such an agreement;

 

		(f)	Notify the Rights Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a
result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading
in the light of the circumstances then existing, or if in the opinion of counsel for the Company it is necessary to supplement
or amend such prospectus to comply with law, and at the request of the Rights Holder promptly prepare and furnish to the Rights
Holder a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter
delivered to the purchasers of such securities, such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances under which they were made or such prospectus, as supplemented or amended, shall comply with law;

 

		(g)	Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities
exchange on which similar securities issued by the Company are then listed;

 

		(h)	Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder
and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

		(i)	Use its best efforts to furnish, at the request of the Rights Holder requesting registration of
Registrable Securities pursuant to this Article 2, on the date that such Registrable Securities are delivered to the underwriters
for sale in connection with a registration pursuant to this Article 2, if such securities are being sold through underwriters,
(i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance
as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters and (ii) a letter dated
such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent
certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters;

 

    8

     

    

 

		(j)	To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities
Act) (a “WKSI”) at the time any request for registration is submitted to the Company in accordance with Section
2.3, if so requested, file an automatic shelf registration statement (as defined in Rule 405 under the Securities Act) (an
 “automatic shelf registration statement”) to effect such registration;

 

		(k)	If (i) the Company determines that it is not a WKSI, (ii) the registration statement is required
to be kept effective in accordance with this Agreement, and (iii) the registration rights of the applicable Rights Holder have
not terminated, promptly amend the registration statement onto a form the Company is then eligible to use or file a new registration
statement on such form, and keep such registration statement effective in accordance with the requirements otherwise applicable
under this Agreement;

 

		(l)	If (i) a registration made pursuant to a shelf registration statement is required to be kept effective
in accordance with this Agreement after the third anniversary of the initial effective date of the shelf registration statement
and (ii) the registration rights of the applicable Rights Holder have not terminated, file a new registration statement with respect
to any unsold Registrable Securities subject to the original request for registration prior to the end of the three year period
after the initial effective date of the shelf registration statement, and keep such registration statement effective in accordance
with the requirements otherwise applicable under this Agreement; and

 

		(m)	Otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations
of the SEC.

 

		2.5	Furnish Information.

 

It shall be a condition precedent
to the obligations of the Company to take any action pursuant to this Article 2 with respect to the Registrable Securities
of the selling Rights Holder that the Rights Holder shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration
of such Rights Holder’s Registrable Securities. The Company shall have no obligation with respect to any registration requested
pursuant to Section 2.1 or Section 2.3 of this Agreement if, as a result of the application of the preceding sentence,
the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration
does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s
obligation to initiate such registration as specified in Section 2.1(a) or Section 2.3(b), whichever is applicable.

 

    9

     

    

 

		2.6	Expenses of Registration.

 

		(a)	Demand Registration. All
                                         expenses (other than underwriting discounts and commissions and ADS issuance and stock
                                         transfer taxes and fees) incurred in connection with registrations, filings or qualifications
                                         pursuant to Section 2.1 for the Rights Holder (which right may be assigned as
                                         provided in Section 2.11), including (without limitation) all registration, filing
                                         and qualification fees, printers’ and accounting fees, fees and disbursements of
                                         counsel for the Company, and the reasonable fees and disbursements of one counsel for
                                         the selling Rights Holder selected by them with the approval of the Company, which approval
                                         shall not be unreasonably withheld, shall be borne by the Company. In addition, the Company
                                         shall be responsible for all of its internal expenses incurred in connection with the
                                         consummation of the transactions contemplated by this Agreement (including, without limitation,
                                         all salaries and expenses of its officers and employees performing legal or accounting
                                         duties), the expense of any annual audit and the fees and expenses incurred in connection
                                         with the listing of the Registrable Securities on any securities exchange as required
                                         hereunder. In no event shall the Company be responsible for any underwriting, broker
                                         or similar fees or commissions of any Rights Holder. Notwithstanding the foregoing, the
                                         Company shall not be required to bear any costs and expenses provided in this Section
                                         2.6(a) for the registration proceeding begun pursuant to Section 2.1, if the
                                         registration request is subsequently withdrawn at the request of the Rights Holder of
                                         a majority of the Registrable Securities to be registered, unless if at the time of such
                                         withdrawal, the Rights Holder has learned of a material adverse change in the condition,
                                         business, or prospects of the Company not known to the Rights Holder at the time of his
                                         request for such registration and have withdrawn his request for registration with reasonable
                                         promptness after learning of such material adverse change (in which case such registration
                                         shall not constitute the use of a demand registration pursuant to Section 2.1);
	 	 	 

		(b)	Piggyback Registration.
                                         All expenses (other than underwriting discounts and commissions and ADS issuance and
                                         stock transfer taxes and fees) incurred in connection with registrations, filings or
                                         qualifications of Registrable Securities pursuant to Section 2.2 for the Rights
                                         Holder, including (without limitation) all registration, filing, and qualification fees,
                                         printers’ and accounting fees, fees and disbursements of counsel for the Company
                                         and the reasonable fees and disbursements of one counsel for the Rights Holder selected
                                         by them with the approval of the Company, which approval shall not be unreasonably withheld,
                                         shall be borne by the Company;
	 	 	 

		(c)	Registration on Form F-3.
                                         All expenses (other than underwriting discounts and commissions and ADS issuance and
                                         stock transfer taxes and fees) incurred in connection with a registrations, filings or
                                         qualifications pursuant to Section 2.3 for the Rights Holder, including (without
                                         limitation) all registration, filing and qualification fees, printers’ and accounting
                                         fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements
                                         of one counsel for the selling Holder or Holders selected by them with the approval of
                                         the Company, which approval shall not be unreasonably withheld, shall be borne by the
                                         Company.

 

    10

     

    

 

		2.7	Underwriting Requirements.

 

In connection with any offering
involving an underwriting of the Company’s capital shares, the Company shall not be required under Section 2.2
to include any of the Rights Holder’s securities in such underwriting unless they accept the terms of the underwriting as
agreed upon between the Company and the underwriters of internationally recognized standing selected by it (or by other persons
entitled to select the underwriters), and then only in such quantity as the underwriters determine in his sole discretion will
not jeopardize the success of the offering by the Company.  If the total amount of the Company Securities, including Registrable
Securities, requested by shareholders to be included in such offering exceeds the amount of securities that the underwriters determine
in his sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering
only that number of such Company Securities, including Registrable Securities, which the underwriters determine in his sole discretion
will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling shareholders
according to the total amount of securities entitled to be included therein owned by each selling shareholder or in such other
proportions as shall mutually be agreed to by such selling shareholders) but in no event shall (i) the amount of Registrable
Securities of the selling Rights Holder included in the offering be reduced below twenty-five percent (25%) of the total amount
of the Registrable Securities included in such offering, or (ii) any other Company Securities held by any shareholder other
than the selling Rights Holder be included if any Registrable Securities held by the selling Rights Holder are excluded. For the
avoidance of doubt, the rights of Rights Holder to be included in such an offering shall be pari passu with each other. If
the Rights Holder disapproves the terms of any underwriting, the Rights Holder may elect to withdraw therefrom by written notice
to the Company and the underwriters delivered at least ten (10) days prior to the effective date of the registration statement. 
Any Registrable Securities excluded or withdrawn from the underwritten offering shall be withdrawn from the registration.

 

		2.8	Delay of Registration.

 

No Rights Holder shall have any
right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy
that might arise with respect to the interpretation or implementation of this Article 2.

 

    11

     

    

 

		2.9	Indemnification.

 

In the event any Registrable
Securities are included in a registration statement under Article 2:

 

		(a)	To the extent permitted by law, the Company will indemnify and hold harmless the Rights Holder,
any underwriter (as such term is defined in the Securities Act) for the Rights Holder and each Person, if any, who controls the
Rights Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages,
or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal
or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based
upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement
or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein
a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation
promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Rights
Holder, underwriter or controlling Person, as incurred, any legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement
contained in this Section 2.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability,
or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld),
nor shall the Company be liable to any Rights Holder, underwriter or controlling Person for any such loss, claim, damage, liability,
or action to the extent that it arises solely out of or is based solely upon a Violation which occurs in reliance upon and in conformity
with written information furnished expressly for use in connection with such registration by any such Rights Holder, underwriter
or controlling Person.

 

		(b)	To the extent permitted by law, the selling Rights Holder that has included Registrable Securities
in a registration will, severally and not jointly, indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of the Securities
Act, any underwriter, any other rights holders selling securities in such registration statement and any controlling Person of
any such underwriter or other Rights Holder, against any losses, claims, damages, or liabilities (joint or several) to which any
of the foregoing Persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar
as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished by the Rights Holder expressly for use in connection with such registration; and the Rights Holder will pay, as incurred,
any legal or other expenses reasonably incurred by any Person intended to be indemnified pursuant to this Section 2.9(b),
in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity
agreement contained in this Section 2.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the Rights Holder, which consent shall not be unreasonably
withheld; provided, that in no event shall any indemnity under this Section 2.9(b) plus any amount under Section 2.9(d)
exceed the net proceeds from the offering out of which such Violation arises received by such Rights Holder, except in the case
of willful fraud by such Rights Holder.

 

    12

     

    

 

		(c)	Promptly after receipt by an indemnified party under this Section 2.9 of notice of the commencement
of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against
any indemnifying party under this Section 2.9, deliver to the indemnifying party a written notice of the commencement thereof
and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the Parties;
provided, however, that an indemnified party (together with all other indemnified Parties which may be represented without conflict
by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any
such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.9 to the extent the indemnifying party is prejudiced as a result thereof, but the
omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified
party otherwise than under this Section 2.9.

 

		(d)	If the indemnification provided for in this Section 2.9 is held by a court of competent jurisdiction
to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then
the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable
by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to
reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with
the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable
considerations; provided, that in no event shall any contribution by the Rights Holder under this Section 2.9(d) plus
any amount under Section 2.9(b) exceed the net proceeds from the offering received by such Rights Holder, except in
the case of willful fraud by such Rights Holder.  The relative fault of the indemnifying party and of the indemnified party
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission.

 

		(e)	Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution
contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the
foregoing provisions, the provisions in the underwriting agreement shall control.

 

    13

     

    

 

		(f)	The obligations of the Company and the Rights Holder under this Section 2.9 shall survive
the completion of any offering of Registrable Securities in a registration statement under this Article 2, and otherwise.

 

		2.10	Reports Under the Exchange Act.

 

With a view to making available
to the Rights Holder the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC
that may at any time permit the Rights Holder to sell securities of the Company to the public without registration or pursuant
to a registration on Form F-3, the Company agrees to:

 

		(a)	make and keep public information available, as those terms are understood and defined in SEC Rule
144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for
the offering of its securities to the general public so long as the Company remains subject to the periodic reporting requirements
under Sections 13 or 15(d) of the Exchange Act;

 

		(b)	file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act; and;

 

		(c)	furnish to any Rights Holder, so long as the Rights Holder owns any Registrable Securities, forthwith
upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after the effective date of the first registration statement filed by the Company), the Securities Act and the Exchange Act
(at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities
may be resold pursuant to Form F-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report
of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably
requested in availing the Rights Holder of any rule or regulation of the SEC which permits the selling of any such securities without
registration or pursuant to such form.

 

		2.11	Assignment of Registration Rights.

 

The rights to cause the Company
to register Registrable Securities pursuant to this Article 2 may be assigned (but only with all related obligations)
by the Rights Holder to a transferee or assignee (i) of at least 100,000 shares of such securities (as adjusted for share
splits, share combinations, share dividends and the like) (or if the transferring Rights Holder owns less than 100,000 shares of
such securities, then all Registrable Securities held by the transferring Rights Holder), (ii) that is a subsidiary, Affiliate,
parent, partner, limited partner, retired partner, member, retired member and/or shareholder of the Rights Holder, (iii) that
is an affiliated fund or entity of the Rights Holder, which means with respect to a limited liability company or a limited liability
partnership, a fund or entity managed by the same manager or managing member or general partner or management company or by an
entity controlling, controlled by, or under common control with such manager or managing member or general partner or management
company, (iv) who is the Rights Holder’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
cousin, nephew, niece, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law (such a relation,
the Rights Holder’s “Immediate Family Member”, which term shall include adoptive relationships), or (v) that
is a trust for the benefit of an individual Rights Holder or the Rights Holder’s Immediate Family Member, provided the Company
is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee
and the securities with respect to which such registration rights are being assigned; and provided, further, that
such assignment shall be effective only if the transferee agrees to be bound by this Agreement and immediately following such transfer
the further disposition of such securities by the transferee or assignee is restricted under the Securities Act.  For the
purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees
and assignees of (x) a partnership who are partners or retired partners of such partnership, or (y) a limited liability
company who are members or retired members of such limited liability company (including Immediate Family Members of such partners
or members who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the
partnership or limited liability company; provided that all assignees and transferees who would not qualify individually
for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving
notices or taking any action under Article 2.

 

    14

     

    

 

		2.12	No Registration Rights to Third Parties.

 

Except otherwise provided in
Section 2.11, from and after the date of this Agreement, the Company shall not, without the prior written consent of
the Rights Holder of Registrable Securities then outstanding, the Company covenants and agrees that it shall not grant, or cause
or permit to be created, for the benefit of any person or entity any registration rights of any kind (whether similar to the demand,
 “piggyback” or Form F-3 registration rights described in this Section 2, or otherwise) relating to
any securities of the Company which are senior to, or on a parity with, those granted to the Rights Holder in this Agreement.

 

		2.13	Termination of Registration Rights.

 

No Rights Holder shall be entitled
to exercise any right provided for in this Article 2 during any period that Rule 144 under the Securities Act is available
for the sale of all of such Rights Holder’s shares without registration without volume or manner of sale limitation.

 

		3.	Miscellaneous

 

		3.1	Effectiveness and Termination.

 

This Agreement shall be effective
as to the Parties as of the date hereof. This Agreement shall terminate upon the termination of the registration rights pursuant
to Section 2.13.

 

		3.2	Conditions Precedent to Registration.

 

The Parties agree and acknowledge
that the Registrable Securities acquired under the Share Purchase Agreement shall not be registered in accordance with Section 2.1,
Section 2.2 or Section 2.3 hereunder until the expiry of the Distribution Compliance Period (as defined
under the Share Purchase Agreement).

 

    15

     

    

 

		3.3	Entire Agreement.

 

This Agreement constitutes the
entire agreement between the Parties pertaining to the subject matter hereof, and any and all other written or oral agreements
relating to the subject matter hereof existing between the Parties are expressly cancelled.

 

		3.4	Successors and Assigns.

 

Except as otherwise provided
in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the Parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the Parties or his respective successors and assigns any rights, remedies, obligations, or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement.

 

		3.5	Amendments and Waivers.

 

Any term of this Agreement may
be amended or waived only with the written consent of each Parties.

 

		3.6	Notices.

 

All notices and other communications
required or permitted by this Agreement shall be in writing and will be effective, and any applicable time period shall commence,
when (a) delivered to the following address by hand or by a nationally recognized overnight courier service (costs prepaid) addressed
to the following address or (b) transmitted electronically to the following facsimile numbers or e-mail addresses, in each case
marked to the attention of the Person (by name or title) designated in Schedule 1 (or to such other address, facsimile number,
e-mail address, or Person as a Party may designate by notice to the other Party).

 

		3.7	Severability.

 

If any provision of this Agreement
is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement will remain in
full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full
force and effect to the extent not held invalid or unenforceable.

 

		3.8	Governing Law.

 

This Agreement and all acts and
transactions pursuant hereto shall be governed, construed and interpreted in accordance with the laws of the State of New York,
without giving effect to principles of conflicts of laws.

 

    16

     

    

 

		3.9	Counterparts.

 

This Agreement may be executed
in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.  Facsimile and e-mailed copies of signatures shall be deemed to be originals for purposes of the effectiveness
of this Agreement.

 

		3.10	Titles and Subtitles.

 

The titles and subtitles used
in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

		3.11	Dispute Resolution.

 

Any dispute, controversy or claim
arising out of or relating to this Agreement, or the interpretation, breach, termination or invalidity thereof, shall, so far as
it is possible, be settled by arbitration in accordance with the UNCITRAL Arbitration Rules as at present in force and as
may be amended by the rest of this Section 3.11. The appointing authority shall be Hong Kong International Arbitration
Centre (“HKIAC”). The seat of the arbitration shall be Hong Kong. There shall be three (3) arbitrators.
The Company, on the one hand, and the Rights Holder, on the other hand, shall be entitled to designate one arbitrator each. The
two arbitrators shall consult with each other to agree upon the selection of a third arbitrator.  The arbitration shall be
conducted in the English language.  Evidence and testimony may be presented in any language, including a language other than
English providing it is accompanied by an English translation thereof (which translation shall have been certified and prepared
or given at the sole cost of the Party offering such evidence or testimony).  The arbitral award shall be in English writing
and, unless the parties to the arbitration agree otherwise, shall state the reasons upon which it is based. The award shall
be final and binding on the parties to the arbitration.

 

		3.12	Rights Cumulative; Specific Enforcement.

 

Each and all of the various rights,
powers and remedies of a Party will be considered to be cumulative with and in addition to any other rights, powers and remedies
which such Party may have at Law or in equity in the event of the breach of any of the terms of this Agreement. Without limiting
the foregoing, the Parties acknowledge and agree irreparable harm may occur for which money damages would not be an adequate remedy
in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached.  It is accordingly agreed that the Parties shall be entitled to injunction to prevent breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement.

 

		3.13	Further Assurances.

 

Upon the terms and subject to
the conditions herein, each Party agrees to use its reasonable best efforts to take or cause to be taken all action, to do or cause
to be done, to execute such further instruments, and to assist and cooperate with the other Party in doing, all things necessary,
proper or advisable under applicable Laws or otherwise to consummate and make effective, in the most expeditious manner practicable,
the transactions contemplated by this Agreement.

 

    17

     

    

 

		3.14	No Waiver.

 

Neither any failure nor any delay
by any party in exercising any right, power, or privilege under this Agreement or any of the documents referred to in this Agreement
will operate as a waiver of such right, power, or privilege, and no single or partial exercise of any such right, power, or privilege
will preclude any other or further exercise of such right, power, or privilege or the exercise of any other right, power, or privilege.
To the maximum extent permitted by applicable laws, (a) no claim or right arising out of this Agreement or any of the documents
referred to in this Agreement can be waived by a Party, in whole or in part, unless made in a writing signed by such Party; (b) a
waiver given by a Party will only be applicable to the specific instance for which it is given; and (c) no notice to or demand
on a Party will (i) waive or otherwise affect any obligation of that Party or (ii) affect the right of the Party giving
such notice or demand to take further action without notice or demand as provided in this Agreement.

 

		3.15	Delays or Omissions.

 

No delay or omission to exercise
any right, power or remedy accruing to any Party under this Agreement, upon any breach or default of any other Party under this
Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting Party nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or
thereafter occurring.  Unless otherwise expressly provided hereunder, any waiver, permit, consent or approval of any kind
or character on the part of any Party of any breach or default under this Agreement, or any waiver on the part of any Party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth
in such writing.

 

		3.16	Counterparts and Electronic Signatures.

 

This Agreement and other documents
to be delivered pursuant to this Agreement may be executed in one or more counterparts, each of which will be deemed to be an original
copy and all of which, when taken together, will be deemed to constitute one and the same agreement or document, and will be effective
when counterparts have been signed by each of the parties and delivered to the other parties.

 

A manual signature on this Agreement
or other documents to be delivered pursuant to this Agreement, an image of which shall have been transmitted electronically, will
constitute an original signature for all purposes. The delivery of copies of this Agreement or other documents to be delivered
pursuant to this Agreement, including executed signature pages where required, by electronic transmission will constitute effective
delivery of this Agreement or such other document for all purposes.

 

[Signature Pages Follow]

 

    18

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement and caused this Agreement to be executed by their respective officers thereunto duly authorized
as of the date first written above.

 

	
         
	THE COMPANY:
	 	 
	 	JMU Limited
	 	 
	 	 	/s/ Xiaoxia Zhu
	 	Name: 	Xiaoxia Zhu
	 	Title: 	Chairperson of the Board of Directors, 

Chief Executive Officer

 

[Signature Page to Registration Rights
Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties have executed
this Registration Rights Agreement as of the date first written above.

 

	 	RIGHTS HOLDER:
	 	 
	 	Mr. Haohan Xu
	 	 
	 	 	/s/ Haohan Xu
	 	Name: 	Haohan Xu

 

[Signature Page to Registration Rights
Agreement]EX-4.2

 Exhibit 4.2 

FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 10th day of April,
2018, by and among Livongo Health, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Capitalized terms used but not defined in this Agreement shall have the respective meanings ascribed to such terms in the Certificate of Incorporation (as defined below). 

RECITALS 

WHEREAS, the Company and certain of the Investors are party to that certain Third Amended and Restated Investors’ Rights
Agreement, dated as of March 14, 2017 (the “Prior Agreement”), to govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the
Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement. 

WHEREAS, the Company and certain Investors are parties to the Series E Preferred Stock Purchase Agreement of even date herewith (the
“Purchase Agreement”); and 
 WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to
induce such Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree to amend and restate the Prior Agreement in its entirety. 

NOW, THEREFORE, the parties hereby agree as follows: 

A. Waiver. The Investors hereby waive, on behalf of themselves and all other stockholders, any and all participation rights, rights of
first offer, rights of first refusal and related notice rights with respect to (i) shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock issued prior to the date hereof,
(ii) shares of Series E Preferred Stock sold pursuant to the Purchase Agreement, as may be amended from time to time, and (iii) shares of Common Stock issued or issuable upon conversion of such shares of Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock, including, without limitation, the right of first offer set forth in Section 4 of the Prior Agreement. 

1. Definitions. For purposes of this Agreement: 

1.1 “7wire Director” has the meaning assigned to such term in the Voting Agreement. 

1.2 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more
general partners (or controlling member thereof), managing members (or controlling member thereof) or managers (or controlling member thereof) of, or that shares the same management 

 
company (or controlling member thereof) with, such Person. As used in this definition, “control” (including, with its correlative meanings, “controlling,” “controlled
by” and “under common control with”) shall mean possession, directly or indirectly, of power to direct or cause the director of management or policies (whether through ownership of securities, by contract or otherwise). 

1.3 “Certificate of Incorporation” means the Company’s Fifth Amended and Restated Certificate of Incorporation, as
amended from time to time. 
 1.4 “Common Requisite Investors” means Major Common Investors holding at least a majority of
the outstanding shares of Common Stock then held by all Major Common Investors. 
 1.5 “Common Stock” means shares of the
Company’s common stock, par value $0.001 per share. 
 1.6 “Conversion Shares” means shares of Common Stock issued or
issuable upon the conversion of Preferred Stock. 
 1.7 “Damages” means any loss, damage, claim or liability (joint or
several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon
(i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any
of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.8 “Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 1.9 “Excluded Registration” means (i) a registration relating to the sale of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating solely to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially
the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon
conversion of debt securities that are also being registered. 
 1.10 “Form S-1”
means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.11 “Form S-3” means such form under the Securities Act as in effect on the date
hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

 1.12 “GAAP” means generally accepted accounting principles in the United
States. 
 1.13 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.14 “Immediate Family Member” means a spouse or child (natural or adopted), of a natural person referred to herein. 

1.15 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.16 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.17 “Key Employee” means and includes the President, chief executive officer, chief financial officer, chief operating
officer, chief scientific officer, chief technology officer, vice presidents of operations, research, development, sales or marketing, or any other individual who performs a significant role in the operations of the Company or a subsidiary or in the
development or conception of any intellectual property rights of the Company or a subsidiary as may be reasonably designated by the Board of Directors, and shall in any event include Glen Tullman. 

1.18 “Lead Series C Investor” means MGHIF or any Affiliate thereof to which it assigns, sells, or otherwise transfers all of
its Registrable Securities. 
 1.19 “Major Common Investor” means any stockholder that, individually or together with such
stockholder’s Affiliates, holds at least 8,000,000 shares of the outstanding shares of Common Stock (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations). 

1.20 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
(a) 2,400,000 shares of Registrable Securities or (b) at least 2,200,000 shares of Series D Preferred Stock (in each case as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after
the date hereof). 
 1.21 “MGHIF” means Merck Global Health Innovation Fund, LLC. 

1.22 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.23 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.24 “Preferred Director” has the meaning assigned to such term in the Certificate of Incorporation. 

 1.25 “Preferred Stock” means the Series A Preferred Stock, the Series B
Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock, collectively. 
 1.26
“Registrable Securities” means: (i) any Common Stock held by an Investor, including Conversion Shares; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise
of any other securities of the Company, in each case acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as)
a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding, however, (x) in all cases, any Registrable Securities sold by a Person in a
transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and (y) for purposes of Section 2, any shares for which registration rights have
terminated pursuant to Section 2.13 of this Agreement. 
 1.27 “Registrable Securities then
outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then
exercisable, convertible and/or exchangeable securities that are Registrable Securities. 
 1.28 “Restricted Securities”
means the securities of the Company required to bear the legend set forth in Section 2.12(b) hereof. 
 1.29
“Requisite Investors” means Investors holding at least seventy-five (75%) percent of the Registrable Securities then outstanding, voting as a single class. 

1.30 “Right of First Refusal and Co-Sale Agreement” means that certain Fourth Amended
and Restated Right of First Refusal and Co-Sale Agreement, dated as of the date hereof, by and among the Company, the Investors and the other stockholders of the Company party thereto, as may be amended from
time to time 
 1.31 “SEC” means the United States Securities and Exchange Commission. 

1.32 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.33 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.34 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.35 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

 1.36 “Series A Preferred Stock” means shares of the Company’s Series A
Preferred Stock, par value $0.001 per share. 
 1.37 “Series B Preferred Stock” means shares of the Company’s Series B
Preferred Stock, par value $0.001 per share. 
 1.38 “Series C Preferred Stock” means shares of the Company’s Series C
Preferred Stock, par value $0.001 per share. 
 1.39 “Series D Preferred Stock” means shares of the Company’s Series D
Preferred Stock, par value $0.001 per share. 
 1.40 “Series E Preferred Stock” means shares of the Company’s Series E
Preferred Stock, par value $0.001 per share. 
 1.41 “Voting Agreement” means that certain Fourth Amended and Restated
Voting Agreement, dated as of the date hereof, by and among the Company, the Investors and the other stockholders of the Company party thereto, as may be amended from time to time. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of
(i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from the Requisite Investors that the Company
file a Form S-1 registration statement with respect to at least twenty five percent (25%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of
Selling Expenses, would exceed $20 million), then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders;
(ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act
covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder
to the Company within twenty (20) days of the date the Demand Notice is given; and (iii) use its reasonable best efforts to cause such registration statement to be declared effective by the SEC as soon as possible, and in each case,
subject to the limitations of Section 2.1(c) and Section 2.3. 
 (b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least fifteen percent (15%) of
the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering
price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon
as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a 

 
Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other
Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and
Section 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a
registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially
detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore necessary to defer the filing of such registration statement, then the Company shall have the right to defer taking action with respect
to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided,
however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder
during such ninety (90) day period other than an Excluded Registration. 
 (d) The Company shall not be obligated to effect, or to
take any action to effect, any registration pursuant to Section 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date
that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to
become effective; (ii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant
to Section 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a
Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations
pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration
expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this
Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has 

 
requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before
the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in
accordance with Section 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s)
will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other
provision of this Section 2.3, if the managing underwriters advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall
so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities,
including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided,
however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of
shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and
its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by 

 
each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless
all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number
of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above in this Section 2.3(b) and no
other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or
corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for
the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of
Section 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than one-third (1/3) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included. 

2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective as promptly as practicable and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of
the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or
delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and
the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriters participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the
Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in
which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit
their right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall
have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such
information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b). All Selling
Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, managers, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if
any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal
or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained
in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld,
delayed or conditioned, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any
such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which such
Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding
if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or
contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any
action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 

 (d) To provide for just and equitable contribution to joint liability under the Securities
Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold
by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not
guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder
pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses) paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by
the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other
information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Requisite Investors, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder to include such securities in any registration unless,
under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the
Holders that are included; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder
hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing
underwriter (such period not to exceed one hundred eighty (180) days; provided, however, that such period may be extended by up to an additional thirty-four (34) days to the extent requested by the managing underwriter in order to address
the requirements of FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto, in situations in which (x) the Company issues an earnings release or material news or a material event relating to the Company
occurs during the last seventeen (17) days of the initial lockup period or (y) prior to the expiration of the initial lockup period the Company announces that it will release earnings results during the
16-day period beginning on the last day of the initial lockup period), (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right, or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held
immediately prior to the effectiveness of the registration statement for the IPO, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities,
whether any such transaction described in clause (i) or (ii) of this Section 2.11 is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this
Section 2.11 shall apply only to the IPO, shall not apply to the 

 
sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers and directors are subject to similar agreements and the
Company uses reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding
Preferred Stock). The underwriters in connection with the IPO are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a
party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with the IPO that are consistent with this Section 2.11 or that are necessary to give
further effect thereto. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

 (c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to
comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering
the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or
transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory
to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge,
or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company
to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer
such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144
or (y) in any transaction in which such Holder distributes, sells, pledges or transfers Restricted Securities to (A) an Affiliate of such Holder or (B) the partners, members, former partners or former members of such Holder in accordance
with their respective partnership, membership or limited liability company interests in such Holder, in each of the foregoing cases, for no consideration; provided that each transferee agrees in writing to be subject to the terms of this
Section 2.12. Each certificate, instrument or book entry evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive
legend set forth in Section 2.12(b), except that such certificate, instrument or book entry shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required
in order to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of
any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the first to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; and 

(b) the fifth anniversary of the IPO. 

3. Information and Inspection Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor: 

(a) as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, (i) a
balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as
included in the Budget (as defined below) for such year, with an explanation of any 

 material differences between such amounts and a schedule as to the sources and applications of funds for
such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with
GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock
issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet
issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of
the Company as being true, complete, and correct; 
 (d) to the extent the Company in its discretion has prepared them, then, as soon as
practicable, but in any event within forty-five (45) days of the end of each month, such monthly financial statements as the Company shall have prepared; 

(e) as soon as practicable, but in any event no later than thirty (30) days prior to the beginning of each fiscal year, a budget and
business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and,
promptly after prepared, any other budgets or revised budgets prepared by the Company; 
 (f) with respect to the financial statements
called for in Section 3.1(a) and Section 3.1(b), an instrument executed by the chief financial officer and chief executive officer on behalf of the Company certifying that such financial statements
were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (except as otherwise set forth in Section 3.1(b)) and fairly present the financial condition of the Company and its results
of operation for the periods specified therein; and 
 (g) such other information relating to the financial condition, business, prospects,
or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information
(i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel, as determined by the Company in its good faith sole discretion. 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the
Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with
the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing
its commercially reasonable best efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company
shall permit each Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company, and provided, further, that MGHIF (or any Affiliate thereof who becomes the Lead Series C
Investor and whose business includes making investments in, and holding securities of, portfolio companies involved in healthcare or life sciences technology) shall not be deemed a competitor of the Company for such purpose), at such Major
Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as
may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good
faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between
the Company and its counsel. 
 3.3 Termination of Information Rights. The covenants set forth in
Section 3.1 and 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor), (b) is or has been independently developed or conceived by
the Investor without use of the Company’s confidential information, or (a) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company;
provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and 

 other professionals to the extent necessary to obtain their services in connection with monitoring its
investment in the Company; (ii) after approval of the Company’s Board of Directors (which approval shall not be unreasonably withheld, conditioned or delayed), to any prospective purchaser of any Registrable Securities from such Investor,
if such prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business,
provided that such Investor informs such Person that such information is confidential and requires such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law (or as requested by
foreign regulatory authority having jurisdiction over such Investor or its Affiliates, including any stock exchange to which the Investor or its Affiliates is subject or submits), provided that the Investor promptly notifies the
Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 3.5 Residuals. The non-use restrictions set forth in the foregoing Section 3.4 shall not apply to an Investor’s use of ideas, concepts and know-how of a nature that is broadly
applicable to companies other than the Company or to the Company’s industry in general, which ideas, concepts and know-how are known by the Investor prior to, or developed or learned by the Investor in
the course of the Investor’s review of the confidential information disclosed hereunder and mentally retained in the unaided memory of the Investor (and not intentionally memorized for the purpose of later recording or use). 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor that is an “accredited investor” (as defined Rule 501(a) under the Securities Act). A Major
Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it deems appropriate. For the avoidance of doubt, a Major Investor that is not an “accredited
investor” shall not have any right to be offered or to purchase New Securities from the Company pursuant to this Section 4. 

(a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the product of (x) the aggregate number of New Securities, times, (y) a fraction, the numerator of which
is the aggregate number of Common Stock then held by such Major Investor (including Conversion Shares) and the denominator of which is the total number of shares of Common Stock of the Company then issued and outstanding (assuming the conversion
into Common Stock of all outstanding shares of Preferred Stock and any other securities convertible into Common Stock, if any, and the exercise of all outstanding stock options and warrants) (the “Pro Rata
Share”). At the expiration of such twenty (20) day period, the Company shall promptly 

 give written notice to each Major Investor that elects to purchase or acquire all the shares available to it
(each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving
written notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the
Major Investors which is equal to the product of (x) the aggregate number of New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors, times, (y) a fraction, the numerator of
which is the aggregate number of shares of Common Stock then held by such Fully Exercising Investor (including Conversion Shares) and the denominator of which is the total number of shares of Common Stock (including Conversion Shares) held by all
Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of
initial sale of New Securities pursuant to Section 4.1(c). 
 (c) If all New Securities referred to in the Offer
Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in
Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer
Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the rights provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1. 

(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in
the Certificate of Incorporation); or (ii) shares of Common Stock issued in the IPO. 
 (e) Notwithstanding any provision hereof to
the contrary, in lieu of complying with the provisions of this Section 4.1 in advance of any issuance of New Securities to any Major Investor, the Company may elect to give notice to the Major Investors within thirty days
after the issuance of New Securities. Such notice shall describe the type, price, and terms of the issuance of New Securities to Persons that are not Major Investors. Each Major Investor shall have twenty (20) days from the date notice is given
to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage ownership position, calculated as set forth in Section 4.1(b), before
giving effect to the issuance of such New Securities. In the event one or more Major Investor declines to purchase the number of New Securities that would maintain such Major Investors’ percentage ownership positions, the New Securities so
declined shall be offered to the fully participating Major Investors on the basis provided in Section 4.1(b). The closing of such sale shall occur within sixty (60) days of the date notice is given to the Major
Investors. 
 4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further
force or effect (i) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or
15(d) of the Exchange Act, or (iii) upon consummation of the IPO, whichever event occurs first. 

 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to obtain within ninety (90) days of the date hereof
and/or maintain, as applicable, from financially sound and reputable insurers: (i) Directors and Officers liability insurance, in the amount of $3 million and on other terms and conditions satisfactory to the Board of Directors (which must
include at least two (2) Preferred Directors), and (ii) term “key-person” insurance on the life of Glen Tullman, in the amount of $3 million and on other terms and conditions
satisfactory to the Board of Directors (which must include at least two (2) Preferred Directors), and the Company will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of
Directors, including at least two (2) Preferred Directors, determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be
cancelable by the Company without prior approval by the Board of Directors, including at least two (2) Preferred Directors. 
 5.2
Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information
and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement in form and substance satisfactory to the Board of Directors (including at least two (2) Preferred Directors) and (ii) each Key Employee to
enter into a one (1) year nonsolicitation agreement, substantially in the form approved by the Board of Directors (including at least two (2) Preferred Directors). In addition, the Company shall not, and shall cause its subsidiaries not
to, amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Board of Directors (including at
least two (2) Preferred Directors). 
 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, all future
employees, directors and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements,
as applicable, providing (i) for vesting of shares over a four (4) year period, with the first twenty five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following thirty six (36) months, provided, however, that for the avoidance of doubt the vesting provisions described herein shall not apply with respect to the restricted stock awards
granted by the Company prior to the date hereof, (ii) for a market stand-off provision substantially similar to that in Section 2.11; and (iii) that the Company may require
such purchaser or recipient to become a party to the Voting Agreement and the Right of First Refusal and Co-Sale Agreement as a condition of purchasing or receiving its shares or exercising its options,
provided, however, that any holder of greater than one percent (1%) of the Company’s Common Stock (assuming conversion of any Preferred Stock) will be required to become a party to such agreements. In addition, unless otherwise
approved by the Board of Directors, including at least two (2) Preferred Directors, the Company shall retain a “right of first refusal” on any transfers of Common Stock by all employees, directors and consultants until the
Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

 5.4 Prohibited Actions. The Company shall not, without the consent of (a) the
Preferred Requisite Investors and the Common Requisite Investors, either directly or indirectly take any of the Prohibited Actions, (b) the Series E Requisite Investors, take any of the Series E Prohibited Actions, (c) the Series D
Requisite Investors, take any of the Series D Prohibited Actions, (d) the Series C Requisite Investors, take any of the Series C Prohibited Actions, (e) the Series B Requisite Investors, take any of the Series B Prohibited Actions or
(f) the Series A Requisite Investors, take any of the Series A Prohibited Actions. Any such consent may be given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or
transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect. Any defined terms used in this Section 5.4 and not defined in this Agreement shall have the meanings
ascribed to such terms in the Certificate of Incorporation. 
 5.5 Board Matters. Unless otherwise determined by the vote of a
majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse each member of the Board of Directors who is not an employee of the Company for
all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with (i) attending meetings of the Board of
Directors and (ii) non-Board of Directors issues related to the Company, to the extent such expenses are incurred at the request of the Company. The Company shall at all times: (i) cause the Bylaws of the
Company to provide that, unless otherwise required by the laws of the State of Delaware, any Preferred Director and the 7wire Director shall have the right to call a meeting of the Board of Directors or stockholders; and (ii) maintain
provisions in the Bylaws or Certificate of Incorporation permitting the Preferred Directors and the 7wire Director to serve on all committees of the Company’s Board of Directors. Unless otherwise approved by the Board of Directors, including at
least two (2) Preferred Directors, no employee of the Company shall serve on either the audit committee or the compensation committee. 

5.6 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may
be. 
 5.7 Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as defined in the Voting Agreement of
even date herewith by among the Company and certain stockholders), the reasonable fees and disbursements of one counsel for the Major Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne
and paid by the Company, in no event to exceed $20,000. At the outset of considering a transaction which, if consummated, would constitute a Sale of the Company, the Company shall use commercially reasonable effort to obtain the ability to share
with the Investor Counsel (and such counsel’s clients) and, if so permitted, shall share the confidential information (including without limitation the initial and all subsequent drafts of memoranda of understanding, letters of intent and other
transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of
the Company. 

 5.8 Indemnification Matters. The Company hereby acknowledges that one (1) or
more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the
Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and
any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the
Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it
irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no
advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a
right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

5.9 Lead Series C Investor Protective Provisions. In addition to any other vote or approval required under the Certificate of
Incorporation, the Company will not (either directly or indirectly, by amendment, merger, consolidation or otherwise) do (or permit its subsidiaries to do) any of the following (collectively, the “Lead Series C Investor Protective Provision
Events”) without obtaining the prior written consent of the Lead Series C Investor: 
 (a) enter into any line of business that
would reasonably be expected to cause an adverse regulatory event for MGHIF and/or its Affiliates with aggregate potential liabilities or damages to MGHIF and/or its Affiliates that are material in relation to the value of the then-ownership of the
Company by MGHIF and its Affiliates but that are in no event less than $15,000,000; or 
 (b) directly or indirectly sell, offer to sell,
or otherwise provide to any third party any prescription drugs (or provide any prescriptions for the same) or otherwise employ or engage as a consultant any individual whose responsibilities on behalf of the Company include writing any prescriptions
or providing any such prescription drugs, in each case for a purpose or in a manner that would reasonably be expected to cause an adverse regulatory event for MGHIF and/or its Affiliates with aggregate potential liabilities or damages to MGHIF
and/or its Affiliates that are material in relation to the value of the then-ownership of the Company by MGHIF and its Affiliates but that are in no event less than $15,000,000; 

 provided, in each case, that within 90 days of the Lead Series C Investor’s knowledge of the
occurrence of the applicable Lead Series C Investor Protective Provision Event, the Lead Series C Investor shall provide written notice to the Company that the applicable adverse regulatory event(s) would reasonably be expected to occur (the
“Lead Series C Investor Notice”), which Lead Series C Investor Notice shall specify the details of such expected regulatory event(s) and the aggregate potential damages thereof to MGHIF and/or its Affiliates. Upon receipt of such
Lead Series C Investor Notice, the Company will have 30 days during which it may remedy such Lead Series C Investor Protective Provision Event, including, without limitation, by (x) exiting any line of business set forth in
Section 5.9(a) above, (y) ceasing to directly or indirectly sell, offer to sell, or otherwise provide to any third party any prescription drugs (or provide any prescriptions for the same) or otherwise employ or engage
as a consultant any individual whose responsibilities on behalf of the Company include writing any prescriptions or providing any such prescription drugs, in each case for a purpose or in a manner as set forth in
Section 5.9(b) above, or (z) taking any other action that would reasonably be expected to cause the aggregate potential damages of such Lead Series C Investor Protective Provision Event to MGHIF and/or its Affiliates
to be less than $15,000,000 or to not be material in relation to the value of the then-ownership of the Company by MGHIF and its Affiliates. In the event that (i) the Lead Series C Investor fails to timely deliver the Lead Series C Investor
Notice or (ii) the Company timely remedies such Lead Series C Investor Protective Provision Event, such Lead Series C Investor Protective Provision Event shall be deemed to have not occurred. 

5.10 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of 7wire (as defined in the Voting Agreement),
DFJ (as defined in the Voting Agreement), General Catalyst (as defined in the Voting Agreement), Kinnevik (as defined in the Voting Agreement), KPCB (as defined in the Voting Agreement), Sapphire (as defined in the Voting Agreement), Microsoft (as
defined in the Voting Agreement), EDBI (as defined in the Voting Agreement), Echo (as defined in the Voting Agreement) and MGHIF, in each case, together with their respective Affiliates (collectively, the “Active Investors”),
is a professional investment fund or an institutional investor and as such invests in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be
conducted). The Company hereby agrees that, to the extent permitted under applicable law, no Active Investor shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Active Investor in any entity
competitive with the Company, or (ii) actions taken by any partner, officer or other representative of such Active Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of
such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized
disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.11 FCPA. The Company hereby agrees that it shall not (and shall not permit any of its subsidiaries or affiliates or any of its or
their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party,
including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act 

 of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery
Act, or any other applicable anti-bribery or anti-corruption law. The Company further agrees that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions
taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable
anti-bribery or anti-corruption law. The Company further agrees that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems
and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its
compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any
other anti-corruption law. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its reasonable best efforts
to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

5.12 Termination of Covenants. The covenants set forth in this Section 5, except for
Section 5.5, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. In addition, the covenants set forth in
Section 5.9 shall terminate and be of no further force or effect at such time as the Lead Series C Investor holds fewer than 25% of the Registrable Securities acquired by it pursuant to the Series C Preferred Stock Purchase
Agreement of the Company, if such time occurs earlier than the events set forth in the first sentence of this Section 5.12. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s
Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least (A) 4,000,000 shares of Registrable Securities (subject to
appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) or (B) at least 2,200,000 shares of Series D Preferred Stock (subject to appropriate adjustment for stock splits, stock dividends,
combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of
Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a
Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and 

 with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this
Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed
in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts; Facsimile. This Agreement may also be executed and delivered by facsimile, electronic mail (including pdf) signature
and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All communications to the Company shall be sent to: 444 N. Michigan Ave., Suite 3400, Chicago, IL 60611, Attention: General Counsel, with a copy (which shall not constitute notice) sent to: Sidley Austin LLP, One South Dearborn, Chicago, IL 60603,
Attention: Gary Gerstman. All communications shall be sent to the other respective parties at their addresses as set forth on Schedule A hereto, or to such email address, facsimile number, or address as subsequently modified by
written notice given in accordance with this Section 6.5. 
 6.6 Amendments and Waivers. Any term of this
Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite
Investors; provided that the Company may in its sole discretion waive compliance with Section 2.12(c); and provided further that any provision hereof may be waived by any waiving party on such party’s own
behalf, without the consent of any other party. 
 Notwithstanding the foregoing, (a) this Agreement may not be amended or terminated and the
observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion, (b) the rights hereunder of
the holders of any series of Preferred Stock with 

 respect to such series shall not be amended or waived in a manner that adversely affects such rights
differently than it affects the rights hereunder of the holders of the other series of Preferred Stock with respect to such other series without the written consent of the Investors then holding a majority of the shares of such adversely affected
series then held by the Investors, and (c) any term of Section 3.2 (with respect to the provisions relating to the Lead Series C Investor) or Section 5.9 hereof may be amended and the
observance of any such term of Section 3.2 or Section 5.9 hereof may be waived (either generally or in a particular instance, and either retroactively or prospectively) with, but only with, the
written consent of the Company and the Lead Series C Investor. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or
waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to
any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
the Company’s Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter
shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to
be bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement. This Agreement (including any
Schedules and Exhibits hereto), the Certificate of Incorporation and the other Transaction Agreements (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement among the parties with respect to the subject
matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the federal and
state courts located within the geographic boundaries of the State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement (“Covered Matters”), (b) agree not to commence any
suit, action or other proceeding arising out of or based upon any Covered Matters except in the state or federal courts 

 located in the State of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a
defense, or otherwise, in any such suit, action or proceeding, any claim that a party is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action
or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter of any Covered Matter may not be enforced in or by such court. Each of the parties to this
Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE SECURITIES OF THE COMPANY HELD BY SUCH PARTY OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND
THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY
EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or
Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any
party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All
remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.13
Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital and private equity investing and therefore review the business plans and related proprietary information of many enterprises, including
enterprises which may have products or services that are adverse to or compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict any Investor or any Affiliate thereof from investing or
participating in any particular enterprise whether or not such enterprise has products or services that are adverse to or compete, directly or indirectly, with those of the Company. 

 6.14 Further Assurances. At any time or from time to time after the date hereof, the
parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in order to evidence or
effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder. 
 6.15
Costs of Enforcement. If any party to this Agreement seeks to enforce its rights under this Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the
prevailing party, including, without limitation, all reasonable attorneys’ fees. 
 6.16 Effect on Prior Agreement. Upon the
execution and delivery of this Agreement by the Company and the Requisite Investors who are party to the Prior Agreement (measured before giving effect to any purchase of shares of Series E Preferred Stock by such Requisite Investors), the Prior
Agreement automatically shall terminate and be of no further force and effect and shall be amended and restated in its entirety as set forth in this Agreement. 

[Remainder of Page Intentionally Left Blank] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	THE COMPANY:
	
	LIVONGO HEALTH, INC.
		
	By: 	 	/s/ Glen Tullman

 
			
	Name:	 	Glen Tullman
	Its:	 	CEO

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	GENERAL CATALYST GROUP VI, L.P.
		
	By: 	 	 General Catalyst Partners VI, L.P.
 its General
Partner

		
	By: 	 	 General Catalyst GP VI, LLC
 its General
Partner

 
			
		
	By: 	 	/s/ Christopher McCain

 
			
	Name:	 	Christopher McCain
	Title:	 	Chief Legal Officer

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	GENERAL CATALYST GROUP VIII, L.P.
		
	By:	 	 General Catalyst Partners VIII, L.P.
 its
General Partner

		
	By:	 	 General Catalyst GP VIII, LLC
 its General
Partner

 
			
		
	By: 	 	/s/ Christopher McCain

 
			
	Name:	 	Christopher McCain
	Title:	 	Chief Legal Officer

  

			
	 GENERAL CATALYST GROUP VIII SUPPLEMENTAL, L.P.

		
	By:	 	 General Catalyst Partners VIII, L.P.
 its
General Partner

		
	By:	 	 General Catalyst GP VIII, LLC
 its General
Partner

 
			
		
	By: 	 	/s/ Christopher McCain

 
			
	Name:	 	Christopher McCain
	Title:	 	Chief Legal Officer

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	KINNEVIK ONLINE AB
		
	By: 	 	/s/ Torun Litzen

 
			
	Name:	 	Torun Litzen
	Title:	 	Director Corporate Communication

  

			
	By: 	 	/s/

 
			
	Name:	 	Joakim Andersson
	Title:	 	Chief Financial Officer

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	KPCB HOLDINGS, INC., AS NOMINEE
		
	By: 	 	/s/ Scott Ryles
		 	(Signature)

 
			
	Name:	 	Scott Ryles
	Title:	 	President and Chairman

 
			
		
	Address:	 	
	 
	
	 

 
			
		
	Email:	 	 

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	 MERK GLOBAL HEALTH INNOVATION FUND, LLC

		
	By: 	 	/s/ William J. Taranto

 
			
		 	(Signature)

 
			
	Name:	 	William J. Taranto
	Its:	 	WJT

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	7WIRE VENTURES LLC – SERIES LIVONGO E
	
	/s/ Lee Shapiro
	By:	 	Lee Shapiro
	Its:	 	Manager

  

			
	7WIRE VENTURES FUND, L.P.
		
	By: 	 	7wire Management, LLC
	Its:	 	Manager

  

			
	By: 	 	/s/ Lee Shapiro

 
			
	Name:	 	Lee Shapiro
	Its:	 	Manager

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	7WIRE VENTURES WANXIANG STRATEGIC FUND I, LLC
		
	By: 	 	7wire Management,
	Its:	 	LLC Manager

  

			
	By: 	 	/s/ Lee Shaprio

 
			
	Name:	 	Lee Shapiro
	Its:	 	Manager

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above 
  

			
	WANXIANG AMERICA CORPORATION
		
	By: 	 	/s/ Paul Cumberland

 
			
	Name:	 	Paul Cumberland
	Title:	 	Director of Investments

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	 SAPPHIRE VENTURES FUND II, L.P.,

a Delaware limited partnership

	
	By: Sapphire Ventures (GPE) II, LLC
		
	By: 	 	/s/ David Hartwig

 
			
	Name:	 	David Hartwig
	Title:	 	Managing Member

  

			
	By: 	 	/s/ Nino Marakovic

 
			
	Name:	 	Nino Marakovic
	Title:	 	Managing Member

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	DFJ VENTURE XI, L.P.
	
	 By: DFJ Venture XI Partners, LLC

Its: General Partner

		
	By: 	 	/s/ Josh Stein

 
			
		 	(Signature)
		
	Name:	 	Josh Stein
	Title:	 	Managing Member

  

			
	DFJ VENTURE XI PARTNERS FUND, LLC
		
	By: 	 	/s/ Josh Stein

 
			
		 	(Signature)
		
	Name:	 	Josh Stein
	Title:	 	Managing Member

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	ZAFFRE INVESTMENTS, LLC
		
	By: 	 	/s/ Adreana Santangelo

 
			
	Name:	 	Adreana Santangelo
	Title:	 	

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	MICROSOFT GLOBAL FINANCE
		
	By: 	 	/s/ Keith Dolliver

 
			
	Name:	 	Keith Dolliver
	Title:	 	Director

  
 [Signature Page to
Investors Rights Agreement] 

 The parties have executed this Fourth Amended and Restated Investors’ Rights Agreement
as of the date first written above. 
  

			
	ECHO HEALTH VENTURES, LLC
		
	By: 	 	/s/ Robert M. Coppedge

 
			
	Name:	 	Robert M. Coppedge
	Title:	 	Chief Executive Officer

  
 [Signature Page to
Investors Rights Agreement] 

 SCHEDULE A 

Investors 
 GENERAL CATALYST GROUP VI, L.P.

 GENERAL CATALYST GROUP VIII, L.P. 
 GENERAL CATALYST GROUP
VIII SUPPLEMENTAL, L.P. 
 7WIRE VENTURES LLC – SERIES EOSHEALTH 

7WIRE VENTURES LLC – SERIES LIVONGO E 
 7WIRE VENTURES
FUND, L.P. 
 7WIRE VENTURES WANXIANG STRATEGIC FUND I, LLC 

7 WIRE VENTURES LLC – SERIES LIVONGO C 
 7WIRE VENTURES LLC
– SERIES LIVONGO D 
 SLOW VENTURES III, LLC 
 GLIKVEST,
LLC 
 KPCB HOLDINGS, INC., AS NOMINEE 
 DFJ VENTURE XI, L.P.

 DFJ VENTURE XI PARTNERS FUND, LLC 
 MERCK GLOBAL HEALTH
INNOVATION FUND, LLC 
 SAPPHIRE VENTURES FUND II, L.P. 

WANXIANG AMERICA CORPORATION 
 COWEN INVESTMENTS LLC COWEN 

PRIVATE INVESTMENTS LP 
 HUMANA INNOVATION ENTERPRISE, INC. 

TCM I, L.P 
 ZAFFRE INVESTMENTS, LLC 

KINNEVIK ONLINE AB 

 BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD 

MICROSOFT GLOBAL FINANCE 
 AMERICAN INVESTMENT HOLDINGS, LLC

 ECHO HEALTH VENTURES, LLC 
 ADNAN ASAR 

JAMES PURSLEY 
 MARIO CHRISTOPHER 

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (SEVF II) 

CARLOS DOMINGUEZ 
 RICAHRD POULTAN 

STEPHEN BOOCHEVER 
 PRAVEEN TOTEJA AND VANDANA TOTEJA AS JOINT
TENANTS 
 ISAAC APPLBAUM 
 RICHARD EIDINGER 

JEFFREY LEERINK 
 VEP, L.P. 

RICK POULTON 
 SCOTT LEISHER 

ISAAC APPLBAUM 
 WILLIAM SAHLMAN 

THE ROBERT A. COMPTON LIVING TRUST DATED 12/15/15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]